Brexucabtagene Autoleucel in Mantle Cell Lymphoma

The conditional marketing approval of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma is based on data from the phase 1/2 EPCORE NHL-1 study.

Robert Stuver, MD, and Zachary D. Epstein-Peterson, MD, spoke with CancerNetwork® about a review article on the treatment of peripheral T-cell lymphoma published in the journal ONCOLOGY®.

KT-333 is under investigation as a treatment for adult patients with relapsed/refractory lymphomas, leukemias, and solid tumors in a phase 1 clinical trial.

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Data from the phase 2 JACKPOT8 PARTB study support the new drug application for golidocitinib as a treatment for relapsed/refractory peripheral T-cell lymphoma in China.

Investigators will assess AFM13 in combination with AB-101 as a treatment for those with relapsed or refractory Hodgkin lymphoma in the phase 2 LuminICE-203 trial.